National trend in prevalence, cost, and discharge disposition after subdural hematoma from 1998-2007

Article · March 2011with17 Reads
DOI: 10.1097/CCM.0b013e3182186ed6 · Source: PubMed
Subdural hematoma is a common type of intracranial hemorrhage, particularly among the elderly, yet, despite the aging U.S. population, little has been published in the last 10 yrs. This study aimed to determine national trends in prevalence, discharge disposition, length of stay, and cost of subdural hematoma over time. Retrospective cohort study. Adult patients hospitalized in the United States between 1998 and 2007 identified in the Nationwide Inpatient Sample. Seven hundred twenty thousand, two hundred ninety-seven adult patients hospitalized in subdural hematoma. None. Discharge disposition, hospital length of stay, and national cost (adjusted to 2007 dollars) were examined. Hospitalizations for subdural hematoma increased from 59,373 (30 per 100,000 hospitalizations) in 1998 to 91,935 (42 per 100,000) in 2007, constituting a 39% per-capita increase. The prevalence of subdural hematoma increased with age (p < .001), particularly among those >80 yrs of age (36% of subdural hematoma cohort), in lower income patients, in patients with acquired abnormalities of the coagulation cascade, and in patients with trauma. Inhospital mortality decreased from 15% to 12% (p = .001), but unsatisfactory discharge disposition increased from 17% to 20% (p < .001). National cost increased from $1.0 to $1.6 billion (p < .001). Unsatisfactory discharge disposition and cost were both independently predicted by higher comorbidity index, alcohol abuse, history of trauma, and acquired abnormal coagulation or platelet factors (p < .05). Neurosurgical intervention for subdural hematoma decreased from 41% in 1998 to 31% in 2007 (p < .001). Subdural hematoma evacuation was associated with decreased mortality but did not significantly protect against poor discharge disposition and was associated with significantly higher cost. The prevalence and total cost for subdural hematoma has increased significantly in the last decade nationwide. Health resource consumption for subdural hematoma is increasing without clear evidence that management practices are leading to improved outcomes.
April 2011 · Neurocritical Care · Impact Factor: 2.44
    Little current data exists regarding outcome, cost, and length of stay (LOS) after subdural hemorrhage (SDH). We sought to examine predictors of discharge disposition, ICU and hospital LOS and direct, indirect, ICU, surgical, and diagnostic costs for SDH. A retrospective review was conducted of 216 SDH patients, aged >18 years admitted to our hospital between 1/2001 and 12/2008. Discharge... [Show full abstract]
    October 2003 · BMJ Clinical Research · Impact Factor: 14.09
      June 2008 · Journal of Emergency Medicine · Impact Factor: 0.97
        Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. The aim of the Evidence-Based Medicine (EBM) Section is to bring the readership clinically relevant and practical... [Show full abstract]
        November 2010 · Archives of internal medicine · Impact Factor: 17.33
          Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern. Outside of clinical trials, few published data describe the magnitude and nature of hemorrhage-related AEs from DAT. To estimate the numbers and rates of emergency department (ED) visits for hemorrhage-related AEs... [Show full abstract]
          Discover more